Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

Targeting tumor's vulnerability yields durable responses in Phase I/II

Trial

SEATTLE, Nov. 21 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX), announced that cumulative preliminary results of a phase I trial combining cisplatin with brostallicin in patients with solid tumors that had relapsed or were resistant to front-line treatment were presented at the Highlights in Oncology meeting in Naples, Italy, on Tuesday, November 20, 2007. Cristina Geroni, Ph.D. of Nerviano Medical Sciences (NMS), which developed brostallicin, summarized the basis for the phase I trial design. The trial is based on data demonstrating tumors with high levels of GSH/GST, common in platinum-resistant disease, are more susceptible to the killing effects of brostallicin. High levels of GSH and GST are associated with resistance to most standard chemotherapy drugs

"Our phase I and II experience with brostallicin in over 160 patients demonstrates encouraging anti-tumor activity in a variety of solid tumors, with more than 50% of the patients experiencing at least disease stabilization," said Steven Weitman, M.D., of Systems Medicine.

The preliminary results from the first 21 patients treated in the phase I combination trial with cisplatin showed similar results, with 14 of the patients experiencing stable disease and half (50%) of those 14 patients having durable stable disease for more than six cycles of therapy. Toxicities were mainly hematological and were manageable and reversible in this heavily pretreated patient population. Phase II studies using this combination in patients resistant to standard therapy are planned.

About the Phase I Study

The phase I, multicenter, dose-escalation study of brostallicin in combination with cisplatin (cDDP) was conducted in patients with recurrent or metastatic solid tumors. Treatment cycles wer
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Selexis SA , a serial innovation ... mammalian cell line development, announced today new data from ... presented at the 10th Annual Cell Line Development ... 10, 2014 at the Double Tree by Hilton Berkeley ... will be presented during an oral presentation: , Title: ...
(Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... Industrial Applications , the global market for industrial enzymes ... 2018, registering a five-year compound annual growth rate (CAGR) ... in the detergent enzyme segment with a CAGR of ... influenced almost every sector of industrial activity, ranging from ...
(Date:7/30/2014)... 30, 2014 Researchers often use microelectronic ... but such devices can do much more – ... such, researchers have looked to patterned assemblies of ... metabolic engineering to characterize – and potentially control ... are envisioned to recreate animal and human physiological ...
(Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... WASHINGTON, Oct. 19 The US and European medical ... growth in 2009 but managed to improve overall net ... improved financial discipline. While medtech has fared better than ... will put increasing strain on the industry,s long-standing business ...
... Co. (NYSE: GRA ) has received approval from ... of the previously announced transactions contemplated by the Agreement and ... to which W. R. Grace & Co.-Conn, a wholly-owned subsidiary ... (OTC Bulletin Board: NZYM ), a manufacturer of ...
... Theoretical work done at the Department of Energy,s Oak ... an unexpected magnetism between two dissimilar materials. The ... significance for the design of future electronic devices for ... ORNL,s Materials Science and Technology Division. The work was ...
Cached Biology Technology:Medtech Industry Successfully Weathering Challenges of Economic Downturn 2Medtech Industry Successfully Weathering Challenges of Economic Downturn 3Medtech Industry Successfully Weathering Challenges of Economic Downturn 4Medtech Industry Successfully Weathering Challenges of Economic Downturn 5Synthetech Announces Bankruptcy Court Approval of Merger With W. R. Grace Subsidiary 2Synthetech Announces Bankruptcy Court Approval of Merger With W. R. Grace Subsidiary 3ORNL theorist part of team that discovers unexpected magnetism 2
(Date:7/30/2014)... Everybody knows the shortest distance between two points is ... that sperm have been taking the familiar axiom to ... usually thought to be intense, with each racing for ... in some species, sperm form cooperative groups that allow ... , A new study, conducted by Heidi Fisher, ...
(Date:7/30/2014)... joint venture between The University of Texas at San ... Center at San Antonio, has selected the winners of ... from UTSA and Lei Huang from the Health Science ... engineered ferritins for tracking and protecting neural stem cells ... focused on finding a treatment for stroke through stem ...
(Date:7/30/2014)... Jackson Laboratory has received a pledge of $1 million ... name the Laboratory,s new Neurobehavioral Biometry Center. ... Center will enable the Laboratory to develop a greater ... the ultimate goal of accelerating the pace of research ... serve as a premier resource for the Laboratory and ...
Breaking Biology News(10 mins):When cooperation counts 2When cooperation counts 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... Our cells, molecules form an intricate network of ... to measure individual molecular reactions outside the cells. ... than in the laboratory, scientists suspect that the ... substantially from external probes. We expected the cellular ...
... School of Medicine researcher will lead the coordinating center ... in the field of stem cell research. Michael L. ... chosen by the National Heart, Lung and Blood Institute ... national experts, which will be called the NHLBI Progenitor ...
... , WALL, N.J., Dec. 3 BIO-key International, ... public safety and finger-based biometric identification solutions, announced that ... Meeting held today approved the sale of the company,s ... the shares voted, 98.6% were cast in favor and ...
Cached Biology News:Looking for the heartbeat of cellular networks 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
... polyclonal antibody raised against a ... Immunogen: SF3B2 (NP_006833, ... partial recombinant protein with GST ... Number: NM_006842 ...
...
Biology Products: